Upregulation of C1s (1.60-fold), C1q (1.53-fold), C2 (2.76-fold), C3 (1.9-fold), and C4b (2.45-fold) indicated that timely complement activation may contribute to COVID-19 in CMs. The gene discussed is C1S; the disease is COVID-19.